Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

104.20 +2.41 (+2.37%)

Streaming Delayed Price Updated: 12:02 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

25 26 Next >

Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates

October 28, 2025

From Incyte

Via Business Wire

Exploring Incyte's Earnings Expectations ↗

October 27, 2025

Via Benzinga

Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System

October 27, 2025

From Incyte and Enable Injections

Via Business Wire

What To Expect From Incyte’s (INCY) Q3 Earnings

October 26, 2025

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings this Tuesday morning. Here’s what you need to know.

Via StockStory

Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis

October 25, 2025

From Incyte

Via Business Wire

Eli Lilly's New Ebglyss Results Back Flexible Treatment Options For Atopic Dermatitis ↗

October 24, 2025

Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for Olumiant in hair regrowth.

Via Benzinga

INCYTE CORP (NASDAQ:INCY) Presents a Value Investing Opportunity with Strong Fundamentals ↗

October 22, 2025

INCYTE CORP (INCY) appears undervalued with strong profitability and a healthy balance sheet. Its low P/E and high ROE suggest a potential value investing opportunity.

Via Chartmill

These S&P500 stocks are gapping in today's session ↗

October 20, 2025

Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Monday. Discover the gap up and gap down stocks in the S&P500 index.

Via Chartmill

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma

October 19, 2025

From Incyte

Via Business Wire

Incyte (INCY) Stock Is Up, What You Need To Know

October 16, 2025

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 1.5% in the afternoon session after the company announced Health Canada's approval of its Opzelura cream for treating atopic...

Via StockStory

Topics Artificial Intelligence

Incyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000 ↗

October 14, 2025

Via The Motley Fool

Topics Regulatory Compliance

Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025

October 12, 2025

From Incyte

Via Business Wire

JPMorgan Elevates Incyte Price Target Amidst Robust Pipeline and Commercial Success, Yet Maintains Cautious "Neutral" Stance

October 10, 2025

JPMorgan Chase & Co. (NYSE: JPM) has recently recalibrated its outlook on the biopharmaceutical giant Incyte Corporation (NASDAQ: INCY), with a notable upward revision of its price target for the...

Via MarketMinute

Topics Economy Intellectual Property

What 14 Analyst Ratings Have To Say About Incyte ↗

October 09, 2025

Via Benzinga

Which S&P500 stocks are gapping on Wednesday? ↗

October 08, 2025

Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Wednesday to uncover the stocks that are gapping in the S&P500 index.

Via Chartmill

Incyte to Report Third Quarter Financial Results

October 08, 2025

From Incyte

Via Business Wire

2 Reasons to Like INCY and 1 to Stay Skeptical

October 02, 2025

Incyte has had an impressive run over the past six months as its shares have beaten the S&P 500 by 19.6%. The stock now trades at $86.01, marking a 38% gain. This was partly due to its solid quarterly...

Via StockStory

Topics Stocks

Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes

September 29, 2025

Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by...

Via MarketMinute

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 24, 2025

From Incyte

Via Business Wire

STRATA Skin Sciences Soars as Landmark Study Reveals Superior Vitiligo Treatment Efficacy

September 23, 2025

STRATA Skin Sciences Inc. (NASDAQ: SSKN) witnessed a dramatic surge in its stock price today, climbing 51.18% following the publication of a groundbreaking peer-reviewed study. The research highlights...

Via MarketMinute

Topics Intellectual Property

Jim Cramer Spotlights These Undervalued S&P 500 Stocks With Growth Potential Amid Skyrocketing Market ↗

September 23, 2025

In a recent episode of "Mad Money," Jim Cramer identified several stocks in the S&P 500 that he believes are undervalued, offering growth potential despite the market's record highs.

Via Benzinga

Topics Stocks

Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer

September 22, 2025

From Incyte

Via Business Wire

Incyte Stock: A Deep Dive Into Analyst Perspectives (11 Ratings) ↗

September 19, 2025

Via Benzinga

FDA Expands Incyte's Opzelura Approval To Treat Atopic Dermatitis In Children ↗

September 19, 2025

FDA approves Incyte's Opzelura cream for children aged two and older with atopic dermatitis, expanding its use beyond teens and adults.

Via Benzinga

Incyte Corp (NASDAQ:INCY) Emerges as a Top Value Investing Candidate ↗

September 19, 2025

Incyte Corp (INCY) presents a strong value investing case with low P/E ratios, robust financial health, and high profitability in the biotech sector.

Via Chartmill

Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis

September 18, 2025

From Incyte

Via Business Wire

Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025

September 17, 2025

From Incyte

Via Business Wire

2 S&P 500 Stocks with Exciting Potential and 1 We Avoid

September 15, 2025

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some...

Via StockStory

Topics Stocks

Uncover the latest developments among S&P500 stocks in today's session. ↗

September 12, 2025

Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive...

Via Chartmill

September 12, 2025

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

25 26 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.